90. 網膜色素変性症 Retinitis pigmentosa Clinical trials / Disease details
臨床試験数 : 130 / 薬物数 : 180 - (DrugBank : 41) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 109
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04864496 (ClinicalTrials.gov) | April 17, 2021 | 21/4/2021 | Effects of Treatment With N- Acetylcysteine on Visual Outcomes in Patients With Retinitis Pigmentosa | Effects of Oral N- Acetylcysteine on Macular Function in Retinitis Pigmentosa; a Phase 2 Randomized Controlled Trial | Retinitis Pigmentosa | Drug: Prescribe N-acetylcysteine tablets;Drug: Prescribe placebo tablets | Shahid Beheshti University of Medical Sciences | NULL | Active, not recruiting | 18 Years | 40 Years | All | 30 | Phase 2 | Iran, Islamic Republic of |
| 2 | NCT03999021 (ClinicalTrials.gov) | June 24, 2019 | 24/6/2019 | FIGHT-RP 1 Extension Study | A Phase 1 Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of N-Acetylcysteine (NAC) in Patients With Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: NAC effervescent tablets | Johns Hopkins University | NULL | Active, not recruiting | 18 Years | N/A | All | 30 | Phase 1 | United States |
| 3 | NCT03063021 (ClinicalTrials.gov) | February 15, 2017 | 16/2/2017 | The FIGHT-RP1 Study | A Phase 1 Open Label Dose Ranging Study to Assess the Safety and Tolerability of N-Acetylcysteine (NAC) in Patients With Retinitis Pigmentosa (FIGHT-RP1 Study) | Retinitis Pigmentosa | Drug: N-Acetyl Cysteine (NAC) | Johns Hopkins University | NULL | Completed | 18 Years | N/A | All | 30 | Phase 1 | United States |